Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515118 | 0.94 | SRC (0.54) | GPR119CYP3A4SRCEGFRNR3C1 | |
| SCHEMBL9950465 | 0.94 | SRC (0.54) | GPR119CYP3A4SRCEGFRNR3C1 | |
| SCHEMBL26811380 | 0.89 | GPR119 (0.46) | GPR119CYP3A4SRCEGFRNR3C1 | |
| SCHEMBL13861580 | 0.88 | SRC (0.48) | GPR119SRCEGFRHCAR1POLB | |
| SCHEMBL13861581 | 0.88 | SRC (0.48) | GPR119SRCEGFRHCAR1POLB | |
| SCHEMBL16254799 | 0.87 | GPR119 (0.59) | GPR119CYP3A4SRCEGFRHCAR1 | |
| SCHEMBL30588316 | 0.87 | GPR119 (0.57) | GPR119CYP3A4SRCEGFRHCAR1 | |
| SCHEMBL13548264 | 0.87 | GPR119 (0.57) | GPR119CYP3A4SRCEGFRHCAR1 | |
| SCHEMBL26117621 | 0.87 | GPR119 (0.57) | GPR119CYP3A4SRCEGFRHCAR1 | |
| SCHEMBL514777 | 0.85 | GPR119 (0.43) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-115304606-B | Degradation agent for simultaneously targeting BTK and GSPT proteins | 清华大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-30 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-107406451-B | Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | 福马治疗股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-8410089-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2399914-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1578751-A1 | PYRROLOPYRIMIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2004056830-A1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | GPR119 3204/4885CYP3A4 1757/4885SRC 3502/4885 |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | GPR119 3356/4885CYP3A4 1808/4885SRC 2491/4885 |
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | GPR119, GPR4, GPR84 | GPR119 1/4885CYP3A4 750/4885SRC 913/4885 |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | GPR119 3102/4885CYP3A4 1725/4885SRC 3354/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | GPR119 3102/4885CYP3A4 1725/4885SRC 3354/4885 |
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | GPR119, GCGR, GPR35 | GPR119 1/4885CYP3A4 1059/4885SRC 2166/4885 |
| US-20230382915-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | GPR119 777/4885CYP3A4 4768/4885SRC 1950/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | GPR119 3102/4885CYP3A4 1725/4885SRC 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.